{"id":391416,"date":"2015-04-23T00:00:00","date_gmt":"2015-04-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0115-biopharma-colorectal-cancer-third-line-advanced-metastatic-decision-base-us-2015\/"},"modified":"2026-05-03T11:26:56","modified_gmt":"2026-05-03T11:26:56","slug":"dbason0115-biopharma-colorectal-cancer-third-line-advanced-metastatic-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0115-biopharma-colorectal-cancer-third-line-advanced-metastatic-decision-base-us-2015\/","title":{"rendered":"Colorectal Cancer (Third-Line Advanced\/Metastatic) | Decision Base | US | 2015"},"content":{"rendered":"<p><em>How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market?<\/em><\/p>\n<p>Patients with advanced\/metastatic colorectal cancer (mCRC) typically receive chemotherapy (with or without biologics) as treatment, which increases overall survival (OS) but can also lead to severe toxicities. Patients in the third-line setting have limited therapeutic options and typically have a reduced quality of life; therefore, physicians must carefully balance any efficacy benefit associated with a therapy with its toxicity profile. The launch of regorafenib (Bayer HealthCare\u2019s Stivarga) and the anticipated launch of TAS-102 (Taiho Pharmaceutical\u2019s Lonsurf) in the United States and Europe will increase the number of viable treatment options for these patients, and those who are <em>RAS <\/em>wild-type can also receive an EGFR inhibitor (such as cetuximab [Bristol-Myers Squibb\/Eli Lilly\/Merck KGaA\u2019s Erbitux] and panitumumab [Amgen\/Takeda Pharmaceutical\u2019s Vectibix]) if they have not received one previously. However, given that the efficacy associated with these therapies is limited, significant opportunity remains for emerging therapies in development for this patient population.<\/p>\n","protected":false},"template":"","class_list":["post-391416","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391416\/revisions"}],"predecessor-version":[{"id":394539,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391416\/revisions\/394539"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}